Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2017

01.08.2017 | original article

Early detection of lung function decrements in children and adolescents with cystic fibrosis using new reference values

verfasst von: Priv. Doz. Dr. Angela Zacharasiewicz, Sabine Renner, Flora Haderer, Michael Weber, Eleonore Dehlink, Zsolt Szepfalusi, Thomas Frischer

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2017

Einloggen, um Zugang zu erhalten

Summary

Interpretation of lung function values in children with cystic fibrosis (CF) depends on the applied reference values. We hypothesize that differences between the new global lung function initiative (GLI) values and the formerly used Zapletal et al. values produce significantly different clinical results. We analyzed 3719 lung function measurements of 108 children and adolescents (n = 54 male; aged 6–18 years) with CF treated between September 1991 and July 2009. Data were analyzed in milliliters (ml) and % predicted (pred.) and interpreted using Zapletal and GLI reference values. Applying GLI compared to Zapletal resulted in significantly lower mean forced expiratory volume in 1s (FEV1)% pred. values: Zapletal 86.6% (SD 20.6), GLI 79.9% (SD 20.3) and 32% (n = 497/1543) were misclassified as normal when using Zapletal. Despite showing no overall differences in FEV1 and forced vital capacity (FVC) between concomitant Pseudomonas detection (PA+) in n = 938 and Pseudomonas negative (PA-) (n = 2781) using either reference PA+ resulted in lower FEV1 and FVC values with increasing age; however, measurement of small airway obstruction with forced expiratory flow at 75% of FVC (FEF75) values – available for Zapletal –showed significant differences. Reassurance regarding lung function when using old reference values may occur with potential clinical significance. Discrepancies in lung function interpretation underline the importance of using uniform and best available reference values.
Literatur
1.
Zurück zum Zitat Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–51.CrossRefPubMed Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–51.CrossRefPubMed
2.
Zurück zum Zitat Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr. 1997;131(6):809–14.CrossRefPubMed Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr. 1997;131(6):809–14.CrossRefPubMed
3.
Zurück zum Zitat Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makholm LM, Rock MJ, Splaingard ML. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol. 2003;36(3):230–40.CrossRefPubMed Farrell PM, Li Z, Kosorok MR, Laxova A, Green CG, Collins J, Lai HC, Makholm LM, Rock MJ, Splaingard ML. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol. 2003;36(3):230–40.CrossRefPubMed
4.
Zurück zum Zitat Davies JC, Alton EW. Monitoring respiratory disease severity in cystic fibrosis. Respir Care. 2009;54(5):606–17.CrossRefPubMed Davies JC, Alton EW. Monitoring respiratory disease severity in cystic fibrosis. Respir Care. 2009;54(5):606–17.CrossRefPubMed
5.
Zurück zum Zitat Enright PL, Beck KC, Sherrill DL. Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med. 2004;169(2):235–8.CrossRefPubMed Enright PL, Beck KC, Sherrill DL. Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med. 2004;169(2):235–8.CrossRefPubMed
6.
Zurück zum Zitat Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J. 2003;22(6):972–9.CrossRefPubMed Gustafsson PM, Aurora P, Lindblad A. Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis. Eur Respir J. 2003;22(6):972–9.CrossRefPubMed
7.
Zurück zum Zitat Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.CrossRefPubMedPubMedCentral Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MS, Zheng J, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Stanojevic S, Stocks J, Bountziouka V, Aurora P, Kirkby J, Bourke S, Carr SB, Gunn E, Prasad A, Rosenfeld M, et al. The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF registry. J Cyst Fibros. 2014;13(3):319–27.CrossRefPubMed Stanojevic S, Stocks J, Bountziouka V, Aurora P, Kirkby J, Bourke S, Carr SB, Gunn E, Prasad A, Rosenfeld M, et al. The impact of switching to the new global lung function initiative equations on spirometry results in the UK CF registry. J Cyst Fibros. 2014;13(3):319–27.CrossRefPubMed
9.
Zurück zum Zitat Taylor-Robinson D, Whitehead M, Diderichsen F, Vebert Olesen H, Pressler T, Smyth R, Diggle P. Author’s response: understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax. 2013;68(3):294–5.CrossRefPubMed Taylor-Robinson D, Whitehead M, Diderichsen F, Vebert Olesen H, Pressler T, Smyth R, Diggle P. Author’s response: understanding the natural progression in %FEV1 decline in patients with cystic fibrosis: a longitudinal study. Thorax. 2013;68(3):294–5.CrossRefPubMed
10.
Zurück zum Zitat Corey M. Power considerations for studies of lung function in cystic fibrosis. Proc Am Thorac Soc. 2007;4(4):334–7.CrossRefPubMed Corey M. Power considerations for studies of lung function in cystic fibrosis. Proc Am Thorac Soc. 2007;4(4):334–7.CrossRefPubMed
11.
Zurück zum Zitat Welsh L, Robertson CF, Ranganathan SC. Increased rate of lung function decline in Australian adolescents with cystic fibrosis. Pediatr Pulmonol. 2014;49(9):873–7.CrossRefPubMed Welsh L, Robertson CF, Ranganathan SC. Increased rate of lung function decline in Australian adolescents with cystic fibrosis. Pediatr Pulmonol. 2014;49(9):873–7.CrossRefPubMed
12.
Zurück zum Zitat Stanojevic S, Bilton D, McDonald A, Stocks J, Aurora P, Prasad A, Cole TJ, Davies G. Global Lung Function Initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis. Eur Respir J. 2015;46(1):262–4.CrossRefPubMed Stanojevic S, Bilton D, McDonald A, Stocks J, Aurora P, Prasad A, Cole TJ, Davies G. Global Lung Function Initiative equations improve interpretation of FEV1 decline among patients with cystic fibrosis. Eur Respir J. 2015;46(1):262–4.CrossRefPubMed
13.
Zurück zum Zitat Kirkby J, Aurora P, Spencer H, Rees S, Sonnappa S, Stocks J. Stitching and switching: the impact of discontinuous lung function reference equations. Eur Respir J. 2012;39(5):1256–7.CrossRefPubMed Kirkby J, Aurora P, Spencer H, Rees S, Sonnappa S, Stocks J. Stitching and switching: the impact of discontinuous lung function reference equations. Eur Respir J. 2012;39(5):1256–7.CrossRefPubMed
14.
Zurück zum Zitat Zapletal A, Paul T, Samánek M. Significance of contemporary methods of lung function testing for the detection of airway obstruction in children and adolescents (author’s transl). Z Erkr Atmungsorgane. 1977;149(3):343–71.PubMed Zapletal A, Paul T, Samánek M. Significance of contemporary methods of lung function testing for the detection of airway obstruction in children and adolescents (author’s transl). Z Erkr Atmungsorgane. 1977;149(3):343–71.PubMed
15.
Zurück zum Zitat American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144(5):1202–18.CrossRef American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis. 1991;144(5):1202–18.CrossRef
16.
Zurück zum Zitat Quanjer PH, Weiner DJ. Interpretative consequences of adopting the Global Lungs 2012 reference equations for spirometry for children and adolescents. Pediatr Pulmonol. 2014;49(2):118–25.CrossRefPubMed Quanjer PH, Weiner DJ. Interpretative consequences of adopting the Global Lungs 2012 reference equations for spirometry for children and adolescents. Pediatr Pulmonol. 2014;49(2):118–25.CrossRefPubMed
17.
Zurück zum Zitat Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. 2004;126(2):412–9.CrossRefPubMed Rosenbluth DB, Wilson K, Ferkol T, Schuster DP. Lung function decline in cystic fibrosis patients and timing for lung transplantation referral. Chest. 2004;126(2):412–9.CrossRefPubMed
18.
Zurück zum Zitat Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: pseudomonas aeruginosa infection. J Clin Epidemiol. 1995;48(8):1041–9.CrossRefPubMed Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: pseudomonas aeruginosa infection. J Clin Epidemiol. 1995;48(8):1041–9.CrossRefPubMed
19.
Zurück zum Zitat Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(8):814–21.CrossRefPubMed Dasenbrook EC, Merlo CA, Diener-West M, Lechtzin N, Boyle MP. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med. 2008;178(8):814–21.CrossRefPubMed
20.
Zurück zum Zitat Bakker EM, Borsboom GJ, van der Wiel-Kooij EC, Caudri D, Rosenfeld M, Tiddens HA. Small airway involvement in cystic fibrosis lung disease: routine spirometry as an early and sensitive marker. Pediatr Pulmonol. 2013;48(11):1081–8.CrossRefPubMed Bakker EM, Borsboom GJ, van der Wiel-Kooij EC, Caudri D, Rosenfeld M, Tiddens HA. Small airway involvement in cystic fibrosis lung disease: routine spirometry as an early and sensitive marker. Pediatr Pulmonol. 2013;48(11):1081–8.CrossRefPubMed
21.
Zurück zum Zitat Lukic KZ, Coates AL. Does the FEF25-75 or the FEF75 have any value in assessing lung disease in children with cystic fibrosis or asthma? Pediatr Pulmonol. 2015;50(9):863–8.CrossRefPubMed Lukic KZ, Coates AL. Does the FEF25-75 or the FEF75 have any value in assessing lung disease in children with cystic fibrosis or asthma? Pediatr Pulmonol. 2015;50(9):863–8.CrossRefPubMed
22.
Zurück zum Zitat Merkus PJ, Tiddens HA, de Jongste JC. Annual lung function changes in young patients with chronic lung disease. Eur Respir J. 2002;19(5):886–91.CrossRefPubMed Merkus PJ, Tiddens HA, de Jongste JC. Annual lung function changes in young patients with chronic lung disease. Eur Respir J. 2002;19(5):886–91.CrossRefPubMed
Metadaten
Titel
Early detection of lung function decrements in children and adolescents with cystic fibrosis using new reference values
verfasst von
Priv. Doz. Dr. Angela Zacharasiewicz
Sabine Renner
Flora Haderer
Michael Weber
Eleonore Dehlink
Zsolt Szepfalusi
Thomas Frischer
Publikationsdatum
01.08.2017
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2017
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-017-1184-0

Weitere Artikel der Ausgabe 15-16/2017

Wiener klinische Wochenschrift 15-16/2017 Zur Ausgabe